In the 1970s, an unknown virus was suspected for documented cases of transfusion-
associated hepatitis, a phenomenon called non-A, non-B hepatitis. In 1989, the infectious …

Since the first antiviral drug, idoxuridine, was approved in 1963, 90 antiviral drugs
categorized into 13 functional groups have been formally approved for the treatment of the …

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with
approximately 71 million chronically infected individuals worldwide. Clinical care for patients …

HCV infection, risk-based screening failed to identify the majority of individuals with HCV
infection due to both clinician and patient barriers.(9-12) Analysis of the 2003-2010 National …

Background: Rapid improvements in hepatitis C virus (HCV) therapy have led to the
approval of multiple oral direct-acting antiviral (DAA) regimens by the US Food and Drug …

Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …

Background Patients who are chronically infected with hepatitis C virus (HCV) and who do
not have a sustained virologic response after treatment with regimens containing direct …

Background Glecaprevir and pibrentasvir are direct-acting antiviral agents with
pangenotypic activity and a high barrier to resistance. We evaluated the efficacy and safety …

The World Health Organization (WHO) Training course on the inpatient management of
severe acute malnutrition includes training modules, training guides, and supporting …

Hepatitis C virus (HCV) is a hepatotropic RNA virus that causes progressive liver damage,
which might result in liver cirrhosis and hepatocellular carcinoma. Globally, between 64 and …